CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Authors
Amato
Anthony Amato
+47 more
Baechler
Bahija Jallal
Bengtsson
Bilgic
Brandon W Higgs
Cappelletti
Chenxiong Le
Choy
Chris Morehouse
Christopher-Stine
Dalakas
David Fiorentino
Greenberg
Greenberg
Greenberg
Higgs
Hua
Icon Health Publications
Isenberg
Jorn Drappa
Kirou
Kotenko
Laura Richman
Liao
Marlon Rebelatto
Mastaglia
McBride
Merrill
Page
Petri
Philip Brohawn
Steven A Greenberg
Szodoray
Walsh
Warren Greth
Wei Zhu
Wendy I White
Wenzel
Xiang Guo
Yao
Yao
Yao
Yao
Yihong Yao
Yin
Zhu
Zong
Publication date
Publisher
'BMJ'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1136%2Fannrheumdis...
Last time updated on 01/04/2019